Ignite Creation Date:
2025-12-25 @ 4:07 AM
Ignite Modification Date:
2026-03-02 @ 5:23 AM
Study NCT ID:
NCT01807520
Status:
COMPLETED
Last Update Posted:
2018-03-13
First Post:
2013-01-23
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-06-20
Start Date Type:
ACTUAL
Primary Completion Date:
2017-01-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-01-03
Completion Date Type:
ACTUAL
First Submit Date:
2013-01-23
First Submit QC Date:
None
Study First Post Date:
2013-03-08
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-12-14
Results First Submit QC Date:
None
Results First Post Date:
2018-03-13
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-02-14
Last Update Post Date:
2018-03-13
Last Update Post Date Type:
ACTUAL